Ethnobotanical Anti-Respiratory Syncytial Virus Drugs

描述(申请人提供)：下呼吸道感染，如 毛细支气管炎和肺炎在儿科和一些成年人中是由 呼吸道合胞病毒。这些疗法包括有争议的利巴韦林 用于治疗或人源化RSV单抗(Synagis)用于预防。 Synagis预防的每一季费用约为5,000美元。在缺席时 作为一种有效的疫苗，RSV仍然是一个严重的健康威胁，必须努力 寻找更有效和更经济的治疗方法。创新的方法 确定了用民族植物(EB)制剂治疗RSV感染的可能性 在这个项目的第一阶段，这个概念有可能减少 目前的治疗费用。在第一阶段，论证了该概念的可行性 通过显著的体外和体内抗RSV活性，哪个更好或 可与利巴韦林相媲美。这种将EB制剂与历史结合使用的方法 作为一种针对疾病的治疗方法已经开发得足够详细，以提供 为进一步开发有效成分作为抗呼吸道合胞病毒制剂奠定了基础。在……里面 第二阶段，这些EB组分中的活性化合物将在化学上 提纯、表征和发展到所需的准备程度 开展这些化合物作为治疗RSV的药物的临床评估 感染。 建议的商业应用：不可用

DESCRIPTION (provided by applicant): Lower respiratory tract infections such as bronchiolitis and pneumonia in pediatrics and some adults are caused by respiratory syncytial virus. The therapies include the controversial ribavirin for treatment or humanized RSV monoclonal antibodies (Synagis) for prevention. The cost per season for Synagis prophylaxis is about US$ 5,000. In the absence of an effective vaccine, RSV remains a serious health threat and effort must be mounted to find effective and more economical therapies. An innovative approach of treating RSV infection with ethnobotanical (EB) preparations was identified in Phase I of this project and this concept has the potential of reducing the current treatment cost. In Phase I, the feasibility of the concept was proved by the significant in vitro and in vivo anti-RSV activity, which was better or comparable to ribavirin. This approach of using EB preparations with historical use as a treatment to target diseases was developed in enough detail to provide a basis for further development of active ingredients as anti-RSV agents. In Phase II, the active compounds in these EB fractions will be chemically purified, characterized and developed to the level of readiness required to launch clinical evaluation of these compounds as therapeutic agents against RSV infections. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE